Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus ZYRTEC ALLERGY.
SEMPREX-D vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine